MIF in the cerebrospinal fluid is decreased during relapsing-remitting while increased in secondary progressive multiple sclerosis
Publikation: Bidrag til tidsskrift › Tidsskriftartikel › Forskning › fagfællebedømt
Standard
MIF in the cerebrospinal fluid is decreased during relapsing-remitting while increased in secondary progressive multiple sclerosis. / Hjæresen, Simone; Sejbaek, Tobias; Axelsson, Markus; Mortensen, Sif Kløvedal; Vinsløv-Jensen, Helle; Pihl-Jensen, Gorm; Novakova, Lenka; Pedersen, Christian Bonde; Halle, Bo; Poulsen, Frantz Rom; Zhang, Mengliang; Benedikz, Eirikur; Frederiksen, Jette Lautrup; Lycke, Jan; Illes, Zsolt; Fex-Svenningsen, Åsa.
I: Journal of the Neurological Sciences, Bind 439, 120320, 2022.Publikation: Bidrag til tidsskrift › Tidsskriftartikel › Forskning › fagfællebedømt
Harvard
APA
Vancouver
Author
Bibtex
}
RIS
TY - JOUR
T1 - MIF in the cerebrospinal fluid is decreased during relapsing-remitting while increased in secondary progressive multiple sclerosis
AU - Hjæresen, Simone
AU - Sejbaek, Tobias
AU - Axelsson, Markus
AU - Mortensen, Sif Kløvedal
AU - Vinsløv-Jensen, Helle
AU - Pihl-Jensen, Gorm
AU - Novakova, Lenka
AU - Pedersen, Christian Bonde
AU - Halle, Bo
AU - Poulsen, Frantz Rom
AU - Zhang, Mengliang
AU - Benedikz, Eirikur
AU - Frederiksen, Jette Lautrup
AU - Lycke, Jan
AU - Illes, Zsolt
AU - Fex-Svenningsen, Åsa
N1 - Publisher Copyright: © 2022 Elsevier B.V.
PY - 2022
Y1 - 2022
N2 - Background: Macrophage migration inhibitory factor (MIF) is involved in the function of both the innate and adaptive immune systems and in neuroprotection and has recently been implicated in multiple sclerosis (MS). Objectives: Determination of MIF levels in the cerebrospinal fluid (CSF) of patients with distinct subtypes of MS and the cellular localization of MIF in human brain tissue. Methods: The levels of MIF were investigated in CSF from patients with clinically isolated syndrome (CIS) (n = 26), relapsing-remitting MS (RRMS) (n = 22), secondary progressive MS (SPMS) (n = 19), and healthy controls (HCs) (n = 24), using ELISA. The effect of disease-modifying therapies in the RRMS and SPMS cohorts were examined. Cellular distribution of MIF in the human brain was studied using immunochemistry and the newly available OligoInternode database. Results: MIF was significantly decreased in treatment-naïve CIS and RRMS patients compared to HCs but was elevated in SPMS. Interestingly, MIF levels were sex-dependent and significantly higher in women with CIS and RRMS. MIF expression in the human brain was localized to neurons, astrocytes, pericytes, and oligo5 oligodendrocytes but not in microglia. Conclusion: The finding that MIF was decreased in newly diagnosed CIS and RRMS patients but was high in patients with SPMS may suggest that MIF levels in CSF are regulated by local MIF receptor expression that affects the overall MIF signaling in the brain and may represent a protective mechanism that eventually fails.
AB - Background: Macrophage migration inhibitory factor (MIF) is involved in the function of both the innate and adaptive immune systems and in neuroprotection and has recently been implicated in multiple sclerosis (MS). Objectives: Determination of MIF levels in the cerebrospinal fluid (CSF) of patients with distinct subtypes of MS and the cellular localization of MIF in human brain tissue. Methods: The levels of MIF were investigated in CSF from patients with clinically isolated syndrome (CIS) (n = 26), relapsing-remitting MS (RRMS) (n = 22), secondary progressive MS (SPMS) (n = 19), and healthy controls (HCs) (n = 24), using ELISA. The effect of disease-modifying therapies in the RRMS and SPMS cohorts were examined. Cellular distribution of MIF in the human brain was studied using immunochemistry and the newly available OligoInternode database. Results: MIF was significantly decreased in treatment-naïve CIS and RRMS patients compared to HCs but was elevated in SPMS. Interestingly, MIF levels were sex-dependent and significantly higher in women with CIS and RRMS. MIF expression in the human brain was localized to neurons, astrocytes, pericytes, and oligo5 oligodendrocytes but not in microglia. Conclusion: The finding that MIF was decreased in newly diagnosed CIS and RRMS patients but was high in patients with SPMS may suggest that MIF levels in CSF are regulated by local MIF receptor expression that affects the overall MIF signaling in the brain and may represent a protective mechanism that eventually fails.
KW - Biomarker
KW - Dimethyl fumarate
KW - Macrophage migration inhibitory factor
KW - MIF
KW - Mitoxantrone
KW - Multiple sclerosis
KW - Neurodegeneration
KW - Neuroinflammation
KW - Relapsing-remitting
KW - Secondary progression
U2 - 10.1016/j.jns.2022.120320
DO - 10.1016/j.jns.2022.120320
M3 - Journal article
C2 - 35717879
AN - SCOPUS:85132391645
VL - 439
JO - Journal of the Neurological Sciences
JF - Journal of the Neurological Sciences
SN - 0022-510X
M1 - 120320
ER -
ID: 345501268